CIC 2000

ExpressOn BioSystems : 

ExpressOn BioSystems Access to molecular technology Products and services for the cutting edge of bio-science research and therapeutics CIC2000 Dr. Peter Estibeiro: Co-Founder and Director

An improved process for the rapid and efficient design of antisense reagents : 

An improved process for the rapid and efficient design of antisense reagents that can cut lead drug development time by over 50% and initial drug development costs from an average £70 million to around £5 million enabling us to address the estimated £900 million market for gene therapy products [USADATA.COM]

What do antisense reagents do? : 

What do antisense reagents do? DNA RNA protein antisense reagent

Why are antisense reagents useful? : 

Pure and Applied Research Used as research tools to understand gene function Used for drug target validation Human Genome Mapping Project will increase the number of potential drug targets from 500 to 10,000 by 2010 Therapeutics Emerging drugs for difficult-to-treat diseases FDA approval for first antisense drug in 1998 Heralded as the most important medical advance since antibiotics Why are antisense reagents useful?

What is our improved design process? : 

A DNA microarray & proprietary analysis software Can be used on standard microarray readers Rapid applicable to mass screening able to cope with number of new targets Efficient higher success rate than computer-aided design reduced downstream testing Cheap uses established equipment & manufacturing processes What is our improved design process? Why is it so good?

Staged roll-out to market : 

Application Drug target validation (service) Drug therapy candidates (licences &/or partnerships) Staged roll-out to market Target Customers Major pharma R&D depts Major pharma Drug development programmes Market Niche UK pharma Brain diseases eg. AD epilepsy stroke Market Share Leader within 2 years First to market Market Size £2.5 B annual UK spend £900 M for non- cancer gene therapies

Why will we succeed? : 

Why will we succeed? Rapid, cheap and effective design process Aggressive share of specific market niches geographical (UK) biological (brain function) Scientific expertise advisory panel of leading neuroscientists Staged roll-out provides revenue during drug development Already a successful company providing contract research services in molecular biology

Who are we? : 

Who are we? Director of Technology Development: Dr Peter Estibeiro PhD Molecular Biology (Leicester) 1987 Senior research fellow and lecturer (Edinburgh) 1995-1999 Founder and Director of ExpressOn BioSystems 1999- Director of Operations: Dr Eleanor Barnard PhD Molecular Virology (Glasgow) 1997 Research Fellow (Edinburgh) 1996-2000 Co-founder and Director of ExpressOn BioSystems 1999- Non-executive Director: to be announced Commercial Director: to be appointed in 2001

Why are we here? : 

Why are we here? £100,000 Edinburgh Technology Fund (ETF) equity investment By mid-2001: validated proprietary technology portfolio of IP & commercialisation strategy £2 million investment 2001-2003: relocate to Midlothian biotech cluster strengthen management team develop proprietary software scale-up to full commercial design process employ additional scientific staff